Natural History and Outcomes of Nonreplaced Aortic Sinuses in Patients With Bicuspid Aortic Valves.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 06 11 2020
revised: 07 03 2021
accepted: 15 03 2021
pubmed: 4 4 2021
medline: 4 2 2022
entrez: 3 4 2021
Statut: ppublish

Résumé

Enlargement of the sinus of Valsalva (SOV) is common in patients with bicuspid aortic valves (BAVs), and management at the time of aortic valve replacement (AVR) and concomitant ascending aorta replacement/repair is controversial. Between January 2000 and July 2017, 400 patients with BAVs underwent AVR and concomitant ascending aorta repair (graft replacement, 79%; aortoplasty, 21%). To assess the impact of the initial SOV dimension on future dilatation and outcomes, patients were stratified into 2 groups: SOV of less than 40 mm (SOV<40 mm) (n = 209) and SOV of 40 mm or larger (SOV≥40 mm) (n = 191). Patients with SOV≥40 mm were older and more often male. At a median follow-up of 8.1 years (interquartile range, 7.4-9.1 years), 6 patients underwent reoperations on the ascending or sinus portion of the aorta due to aneurysmal dilatation, and enlargement of the sinus was the primary indication for operation in 1 patient. Adjusted analysis showed that baseline SOV and SOV dimension over time were not associated with late outcomes. A gradual increase in SOV diameter over time was identified (P = .004). Patients with smaller baseline SOV diameters showed an initial early decrease in diameter, followed by gradual increase, whereas those with larger baseline diameters had a stable early phase, followed by gradual dilatation. Ascending aorta replacement may lead to an initial remodeling/stabilizing effect on the spared bicuspid aortic root, which is more pronounced in patients with lower SOV diameters. In addition, our data demonstrate that the retained aortic sinuses enlarge slowly, and within the limited follow-up of our study, SOV diameter was not a risk factor for survival or reoperation.

Sections du résumé

BACKGROUND BACKGROUND
Enlargement of the sinus of Valsalva (SOV) is common in patients with bicuspid aortic valves (BAVs), and management at the time of aortic valve replacement (AVR) and concomitant ascending aorta replacement/repair is controversial.
METHODS METHODS
Between January 2000 and July 2017, 400 patients with BAVs underwent AVR and concomitant ascending aorta repair (graft replacement, 79%; aortoplasty, 21%). To assess the impact of the initial SOV dimension on future dilatation and outcomes, patients were stratified into 2 groups: SOV of less than 40 mm (SOV<40 mm) (n = 209) and SOV of 40 mm or larger (SOV≥40 mm) (n = 191).
RESULTS RESULTS
Patients with SOV≥40 mm were older and more often male. At a median follow-up of 8.1 years (interquartile range, 7.4-9.1 years), 6 patients underwent reoperations on the ascending or sinus portion of the aorta due to aneurysmal dilatation, and enlargement of the sinus was the primary indication for operation in 1 patient. Adjusted analysis showed that baseline SOV and SOV dimension over time were not associated with late outcomes. A gradual increase in SOV diameter over time was identified (P = .004). Patients with smaller baseline SOV diameters showed an initial early decrease in diameter, followed by gradual increase, whereas those with larger baseline diameters had a stable early phase, followed by gradual dilatation.
CONCLUSIONS CONCLUSIONS
Ascending aorta replacement may lead to an initial remodeling/stabilizing effect on the spared bicuspid aortic root, which is more pronounced in patients with lower SOV diameters. In addition, our data demonstrate that the retained aortic sinuses enlarge slowly, and within the limited follow-up of our study, SOV diameter was not a risk factor for survival or reoperation.

Identifiants

pubmed: 33811890
pii: S0003-4975(21)00562-2
doi: 10.1016/j.athoracsur.2021.03.037
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

527-534

Informations de copyright

Copyright © 2022 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Sri Harsha Patlolla (SH)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

Hartzell V Schaff (HV)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota. Electronic address: schaff@mayo.edu.

Gabor Bagameri (G)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

Joseph A Dearani (JA)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

Kevin L Greason (KL)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

Richard C Daly (RC)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

Juan A Crestanello (JA)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

John M Stulak (JM)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

Katherine S King (KS)

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.

Alberto Pochettino (A)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

Nishant Saran (N)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH